A number of other analysts have also recently weighed in on ADHD. Roth Capital set a $8.00 target price on shares of Alcobra and gave the stock a buy rating in a research note on Saturday, October 1st. Piper Jaffray Cos. cut shares of Alcobra from an overweight rating to a neutral rating and decreased their target price for the stock from $10.00 to $3.00 in a research note on Thursday, September 29th. Cantor Fitzgerald cut shares of Alcobra from a buy rating to a hold rating and set a $2.00 target price on the stock. in a research note on Thursday, September 29th. Zacks Investment Research raised shares of Alcobra from a sell rating to a hold rating in a research note on Tuesday, July 26th. Finally, Jefferies Group reaffirmed a buy rating on shares of Alcobra in a research note on Thursday, August 25th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the company. Alcobra currently has an average rating of Hold and an average target price of $6.47.
Alcobra (NASDAQ:ADHD) opened at 2.49 on Friday. The company’s market capitalization is $68.63 million. The firm has a 50-day moving average price of $4.14 and a 200-day moving average price of $4.42. Alcobra has a 12 month low of $1.95 and a 12 month high of $8.78.
Alcobra (NASDAQ:ADHD) last posted its earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. On average, equities analysts anticipate that Alcobra will post ($0.94) earnings per share for the current fiscal year.
Several hedge funds have recently modified their holdings of the company. Stifel Financial Corp boosted its stake in shares of Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares in the last quarter. Jefferies Group LLC purchased a new position in Alcobra during the second quarter valued at about $533,000. Palo Alto Investors LLC raised its position in Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the last quarter. BlackRock Fund Advisors raised its position in Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock valued at $1,621,000 after buying an additional 6,516 shares during the last quarter. Finally, VHCP Management LLC raised its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares during the last quarter. 73.69% of the stock is currently owned by institutional investors.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.